Somatotropin
PreclinicalSmall molecule
Somatotropin is one of 7 small molecule programs targeting Turner syndrome. It is currently in Preclinical.
1
Indications
5
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Turner Syndrome
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Voxzogo
BioMarin PharmaceuticalPhase 2
Activella
Eli LillyPreclinical
IC-Green
PProvepharm SAS
Preclinical
Lonapegsomatropin
AAscendis Pharma Endocrinology Division A/S
Phase 2
Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Preclinical
Somatotropin
FFederico II University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Growth2 trials
Heart Failure1 trial
Growth Hormone Deficiency1 trial
Turner syndrome1 trial
Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome
Completed·—·N/A·NCT01367834·17 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Somatotropin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- FFederico II University